Which has grown faster, HRMY or RXRX?

Over the past five years, RXRX grew revenue faster — HRMY at a 32.47% CAGR versus RXRX at 45.50%.

Is HRMY or RXRX more profitable?

HRMY runs the higher net margin — HRMY at 18.88% versus RXRX at -945.92%.

How have HRMY and RXRX total returns compared?

Over the past 5 years, HRMY delivered 0.91% and RXRX delivered -25.86% annualized total return. Past performance doesn't predict future results.

Harmony Biosciences Holdings, Inc. (HRMY) vs Recursion Pharmaceuticals, Inc. (RXRX)

A side-by-side comparison of Harmony Biosciences Holdings, Inc. and Recursion Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

HRMY

Harmony Biosciences Holdings, Inc.

$2.30B

$39.65HealthcareDelayed quote: Oct 6, 2026, 10:00 AM EDT

RXRX

Recursion Pharmaceuticals, Inc.

$2.48B

$4.72HealthcareDelayed quote: Oct 6, 2026, 10:00 AM EDT

Total return — HRMY vs RXRX

growth of $100 · dividends reinvested · last 5y

HRMY +41.2% (+7.1%/yr)RXRX -73.4% (-23.3%/yr)HRMY compounded faster over this window

Log scale — wide-divergence pair

HRMY RXRX

HRMY vs RXRX: by the numbers

•RXRX is the larger company ($2.48B vs $2.30B market cap).
•HRMY is profitable (18.88% net margin) while RXRX runs a net loss (-945.92%).
•RXRX grew revenue faster over the past five years (45.50% vs 32.47% CAGR).

Metrics side by side

Valuation

Metric	HRMY	RXRX
P/E ratio	12.87	N/A
Forward P/E	10.06	N/A
P/S ratio	2.39	45.16
P/B ratio	2.30	2.71
EV / EBITDA	7.42	N/A
FCF yield	15.46%	N/A

Profitability

Metric	HRMY	RXRX
Gross margin	75.42%	-61.96%
Operating margin	24.03%	-867.87%
Net margin	18.88%	-945.92%
ROE	18.14%	-56.71%
ROIC	14.96%	-49.78%

Growth (annualized)

Metric	HRMY	RXRX
Revenue CAGR (5Y)	32.47%	45.50%
FCF CAGR (5Y)	48.43%	N/A
Total return CAGR (5Y)	0.91%	-25.86%

Frequently asked

Which has grown faster, HRMY or RXRX?: Over the past five years, RXRX grew revenue faster — HRMY at a 32.47% CAGR versus RXRX at 45.50%.
Is HRMY or RXRX more profitable?: HRMY runs the higher net margin — HRMY at 18.88% versus RXRX at -945.92%.
How have HRMY and RXRX total returns compared?: Over the past 5 years, HRMY delivered 0.91% and RXRX delivered -25.86% annualized total return. Past performance doesn't predict future results.

Go deeper

Full HRMY analysis Full RXRX analysis Interactive comparison tool

Dig into the metrics

Harmony Biosciences P/E ratio Harmony Biosciences ROE Recursion Pharmaceuticals ROE Harmony Biosciences operating margin Recursion Pharmaceuticals operating margin Harmony Biosciences revenue growth Recursion Pharmaceuticals revenue growth Harmony Biosciences free cash flow Recursion Pharmaceuticals free cash flow

Harmony Biosciences & Recursion Pharmaceuticals appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.